FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892025671> ?p ?o ?g. }

• W2892025671 endingPage "285" @default.
• W2892025671 startingPage "274" @default.
• W2892025671 abstract "Renal fibrosis is the most common pathway leading to end-stage renal disease. It is characterized by excess extracellular matrix (ECM) accumulation and renal tissue damage, subsequently leading to kidney failure. Asperulosidic acid (ASPA), a bioactive iridoid glycoside, exerts anti-tumor, anti-oxidant, and anti-inflammatory activities, but its effects on renal fibrosis induced by unilateral ureteral obstruction (UUO) have not yet been investigated. This study aimed to investigate the protective effect of ASPA on renal fibrosis induced by UUO, and to explore its pharmacological mechanism. Thirty-six Sprague-Dawley (SD) rats were randomly divided into six groups: sham group, UUO model group, three ASPA treatment groups (10, 20, and 40 mg/kg), and captopril group (20 mg/kg). Rats were administered vehicle, ASPA or captopril intraperitoneally once a day for 14 consecutive days. Urea nitrogen (BUN), uric acid (UA) and inflammatory factors in serum samples were evaluated on the 7th, 10th, and 14th day after renal fibrosis induction. In addition, the 12 h urine was collected to test the content of urinary protein (upro) on the 14th day. The obstructive renal tissues were collected for pathological analysis (hematoxylin and eosion (H&E) staining and Masson's Trichrome staining) and immunohistochemical analysis on the 14th day after renal fibrosis induction. The mRNA expression of related factors and the protein levels of smad2, smad3, and smad4 were measured in UUO-induced rats by real time PCR and Western blot, respectively. The levels of BUN, UA, and upro were elevated in UUO-induced rats, but ASPA treatment improved renal function by reducing the levels of BUN, UA, and upro. The protein levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-6, as well as the mRNA levels of TNF-α, IL-1β, IL-6, monocyte chemoattractant protein-1 (MCP-1) and interferon-γ (IFN-γ), were decreased after ASPA administration (10, 20 and 40 mg/kg) in a dose-dependent manner. The ASPA exerted an alleviation effect on the inflammatory response through inhibition of nuclear factor-kappa B (NF-κB) pathway. In addition, reductions in α-smooth muscle actin (α-SMA), collagen III, and fibronectin expression were observed after ASPA administration at doses of 20 and 40 mg/kg. Furthermore, the renal expression of transforming growth factor-β1 (TGF-β1), smad2, smad3, and smad4 was down-regulated by ASPA treatment at doses of 20 and 40 mg/kg. ASPA possessed protective effects on renal interstitial fibrosis in UUO-induced rats. These effects may be through inhibition of the activation of NF-κB and TGF-β1/smad2/smad3 signaling pathways." @default.
• W2892025671 created "2018-09-27" @default.
• W2892025671 creator A5002233203 @default.
• W2892025671 creator A5011729669 @default.
• W2892025671 creator A5023662538 @default.
• W2892025671 creator A5027873831 @default.
• W2892025671 creator A5028425919 @default.
• W2892025671 creator A5031197115 @default.
• W2892025671 creator A5035532117 @default.
• W2892025671 creator A5040436424 @default.
• W2892025671 creator A5073371361 @default.
• W2892025671 date "2019-02-01" @default.
• W2892025671 modified "2023-10-16" @default.
• W2892025671 title "Anti-renal fibrosis effect of asperulosidic acid via TGF-β1/smad2/smad3 and NF-κB signaling pathways in a rat model of unilateral ureteral obstruction" @default.
• W2892025671 cites W1573363608 @default.
• W2892025671 cites W1862366351 @default.
• W2892025671 cites W1990196129 @default.
• W2892025671 cites W1993720885 @default.
• W2892025671 cites W2040903212 @default.
• W2892025671 cites W2071771778 @default.
• W2892025671 cites W2072860244 @default.
• W2892025671 cites W2078890859 @default.
• W2892025671 cites W2083893575 @default.
• W2892025671 cites W2120897563 @default.
• W2892025671 cites W2122364630 @default.
• W2892025671 cites W2123073085 @default.
• W2892025671 cites W2156808480 @default.
• W2892025671 cites W2252555507 @default.
• W2892025671 cites W2252909698 @default.
• W2892025671 cites W2261586786 @default.
• W2892025671 cites W2332184035 @default.
• W2892025671 cites W2414331808 @default.
• W2892025671 cites W2465230353 @default.
• W2892025671 cites W2469041174 @default.
• W2892025671 cites W2473580248 @default.
• W2892025671 cites W2567031164 @default.
• W2892025671 cites W2581980537 @default.
• W2892025671 cites W2585229681 @default.
• W2892025671 cites W2592043891 @default.
• W2892025671 cites W2592205759 @default.
• W2892025671 cites W2593451280 @default.
• W2892025671 cites W2593791388 @default.
• W2892025671 cites W2602308256 @default.
• W2892025671 cites W2611898194 @default.
• W2892025671 cites W2618947559 @default.
• W2892025671 cites W2736904933 @default.
• W2892025671 cites W2743810405 @default.
• W2892025671 cites W2744403052 @default.
• W2892025671 cites W2757722557 @default.
• W2892025671 cites W2767407342 @default.
• W2892025671 cites W2767932648 @default.
• W2892025671 cites W2772075695 @default.
• W2892025671 cites W2772276059 @default.
• W2892025671 cites W2797499614 @default.
• W2892025671 cites W2806528372 @default.
• W2892025671 cites W2807900389 @default.
• W2892025671 doi "https://doi.org/10.1016/j.phymed.2018.09.009" @default.
• W2892025671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30668407" @default.
• W2892025671 hasPublicationYear "2019" @default.
• W2892025671 type Work @default.
• W2892025671 sameAs 2892025671 @default.
• W2892025671 citedByCount "38" @default.
• W2892025671 countsByYear W28920256712019 @default.
• W2892025671 countsByYear W28920256712020 @default.
• W2892025671 countsByYear W28920256712021 @default.
• W2892025671 countsByYear W28920256712022 @default.
• W2892025671 countsByYear W28920256712023 @default.
• W2892025671 crossrefType "journal-article" @default.
• W2892025671 hasAuthorship W2892025671A5002233203 @default.
• W2892025671 hasAuthorship W2892025671A5011729669 @default.
• W2892025671 hasAuthorship W2892025671A5023662538 @default.
• W2892025671 hasAuthorship W2892025671A5027873831 @default.
• W2892025671 hasAuthorship W2892025671A5028425919 @default.
• W2892025671 hasAuthorship W2892025671A5031197115 @default.
• W2892025671 hasAuthorship W2892025671A5035532117 @default.
• W2892025671 hasAuthorship W2892025671A5040436424 @default.
• W2892025671 hasAuthorship W2892025671A5073371361 @default.
• W2892025671 hasConcept C104317684 @default.
• W2892025671 hasConcept C126322002 @default.
• W2892025671 hasConcept C134018914 @default.
• W2892025671 hasConcept C142724271 @default.
• W2892025671 hasConcept C163031210 @default.
• W2892025671 hasConcept C185592680 @default.
• W2892025671 hasConcept C2776415932 @default.
• W2892025671 hasConcept C2778176769 @default.
• W2892025671 hasConcept C2779881121 @default.
• W2892025671 hasConcept C2780091579 @default.
• W2892025671 hasConcept C2780559512 @default.
• W2892025671 hasConcept C55493867 @default.
• W2892025671 hasConcept C71924100 @default.
• W2892025671 hasConcept C98274493 @default.
• W2892025671 hasConceptScore W2892025671C104317684 @default.
• W2892025671 hasConceptScore W2892025671C126322002 @default.
• W2892025671 hasConceptScore W2892025671C134018914 @default.
• W2892025671 hasConceptScore W2892025671C142724271 @default.
• W2892025671 hasConceptScore W2892025671C163031210 @default.
• W2892025671 hasConceptScore W2892025671C185592680 @default.
• W2892025671 hasConceptScore W2892025671C2776415932 @default.

• next